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IMMUNOMODULATORY DRUGS (IMiDs) IN MULTIPLE MYELOMA: 
MECHANISM OF ACTION AND CLINICAL IMPLICATIONS 
MENGNI XU 
 
ABSTRACT 	 Immunomodulatory drugs (IMiDs) are a class of drugs, derived from the 
teratogenic compound thalidomide, that have made a major impact on treatment of many 
diseases, from multiple myeloma to assorted inflammatory diseases. From its dark 
beginnings as a teratogenic agent that caused phocomelia in newborn infants, thalidomide 
has resurged decades later as a potent immunomodulatory agent with widespread anti-
inflammatory and anti-tumor effects. Research examining Thalidomide’s effects in vitro 
on malignant myeloma cells has led to the development of newer analogs, lenalidomide 
and pomalidomide, both of which are now available on the market. Clinically, these 
drugs have had a tremendous impact on patient progression-free survival, especially 
when administered in conjunction with other novel agents. Despite the numerous 
properties that have been reported for IMiDs, until recently, little was known about their 
mechanism of action. Knowledge of likely only one of IMiDs’ direct mechanism of 
action has not only opened up opportunities for additional discoveries, but also propelled 
research to better characterize genetic profiles of multiple myeloma patients and potential 
biomarkers of disease progression and response to treatment. This thesis will attempt to 
review the history and literature behind the biological mechanisms of IMiDs, the clinical 
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risks and benefits of using such drugs as treatment for cancer, and future directions for 
areas of research. 
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INTRODUCTION 
Multiple myeloma (MM) is a cancer caused by malignant plasma B-cells and is 
one of the most prevalent lymphoid malignancies diagnosed in the United States, 
accounting for nearly 10% of all hematological diseases diagnosed and causing 2% of all 
cancer-related deaths (Wang et al., 2015). The disease often occurs in older adults. Age-
adjusted, multiple myeloma occurs in nearly 7 out of every 100,000 men and 4.6 out of 
every 100,000 women (Wang et al., 2016). As of today, with current treatment options, 
median survival for newly-diagnosed multiple myeloma is 44.8 months (Wang et al., 
2016). 
B-cells are important components of adaptive and humoral immunity and help the 
body fight off bacterial infections and other foreign agents. They originate as 
hematopoietic stem cells (HSCs) in the bone marrow and differentiate into common 
lymphoid progenitor cells (CLPs), the precursor cells to developing immature B-cells 
(Kondo, 2010). Before leaving the marrow however, these B-cells that produce a certain 
specific B-cell receptor (BCR) that undergoes several rounds of selection to eliminate 
cells that are self-intolerant and can bind self-antigens (Lebien et al., 2008; Pelanda et al., 
2012). At this stage, as immature B-cells, they are free to exit the bone marrow and 
circulate to the germinal centers in the spleen, where they differentiate into either 
follicular B-cells (residing in the center) or marginal zone B-cells (in the periphery), 
depending on signals received from neighboring cells, and become fully mature or naive 
B-cells (Loder et al., 1999). 
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MM occurs when plasma cells in the bone marrow become cancerous, divide 
uncontrollably, and develop into multiple plastocytomas, tumors of plasma cells. 
Clinically, multiple myeloma presents with bone pain, anemia (due to a lack of red blood 
cell production), thrombocytopenia (due to lack platelet production), hypercalcemia (and 
subsequence neurological issues), osteoporosis, and bone-breakage (Kumar, 2013). These 
manifestations of MM occur because the cancerous plasma cells start to crowd out other 
hematopoietic cells, limiting their function, and release substances to increase osteoclast 
activity, causing bone resorption and pathological bone lesions. In addition, MM patients 
are also, unsurprisingly, at high risk for infections as multiple myeloma cells do not 
produce antibodies that help fight infection (Kumar, 2013). Instead, they produce 
millions of copies of the same monoclonal antibody that can circulate the body and attack 
other organs, like the kidney, and deposit as abnormal protein aggregates called amyloid 
in places like the heart and the kidney (Kumar, 2013).  
Even with treatment, MM patients often relapse. Their tumors become more 
aggressive and their disease symptoms more severe. In many such cases, immediate 
treatment along with additional supportive care is required. The disease is monitored 
through measurement of serum levels of monoclonal (M) protein, a protein produced by 
malignant plasma cells that circulates and causes blood hyperviscosity and possible renal 
failure (Kyle et al., 2008). In some cases, cytogenic studies are conducted, to see if 
patients carry mutations that make their disease particularly high-risk (Sonneveld et al., 
2016). These patients are put on more intensive therapy while lower-risk patients can 
benefit from less intensive therapies. Unfortunately, despite the many advances in 
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treatment options and increased hospital care provided, MM is not a curable disease. 
Patients’ lives can be extended by 3-5 years if they remain on maintenance therapies; 
however, more advanced and potent therapies are needed to not only increase duration of 
progression-free survival and overall survival, but also improve patients’ quality of life. 
 
Treatments of Multiple Myeloma and the use of IMiDs in Modern Therapies 
 Although multiple myeloma is usually a fatal disease, over the decades there have 
been treatment options available that have increased progression-free survival rate in 
patients.  
In the 1960s, a melphalan (a chemotherapeutic drug) and prednisone combination 
therapy was prescribed to combat the disease with some success (Rajkumar, 2005). In the 
1980s, the autologous stem cell transplantation procedure (ASCT) became available as a 
treatment option, pending patient eligibility as a transplant recipient (Rajkumar, 2005). 
ASCT followed by high-dose chemotherapy significantly increased patient survival yet 
unfortunately did not result in lasting cures.  
The real breakthrough in multiple myeloma treatment occurred, however, in the 
early-mid 2000s when thalidomide, the infamous teratogenic drug prescribed for 
pregnant mothers, was approved by the FDA for the treatment of multiple myeloma. This 
radical decision to allow such a drug on the market stemmed from multiple studies in the 
late 1990s that demonstrated that thalidomide increased T-lymphocyte production and 
natural killer (NK) cell activity (Haslett et al, 1998), decreased production of cytokines 
like tumor-necrosis-factor α (TNF-α) (Sampaio et al., 1991), and inhibited angiogenesis 
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(D’Amato, 1994). Subsequent clinical trials showed that thalidomide, especially when 
used in combination with other chemotherapeutic drugs after ASCT therapy, resulted in 
improved progression-free survival and overall survival of MM patients (Wang et al, 
2015). Thalidomide, since then, has become a standard component of multiple myeloma 
treatment.  
 
 
 
 
 
 
 
 
 
 
Due to the success of Thalidomide clinically, further pharmacological studies 
were initiated to investigate whether thalidomide’s chemical structure could be 
chemically altered to improve efficacy and potency, with less toxicity. These efforts, 
notably by the pharmaceutical company Celgene Corporation, led to the development of 
thalidomide analogues like lenalidomide and pomalidomide (Figure 1). Collectively 
called immunomodulatory drugs (IMiDs) in the literature, these new derivatives of 
Figure 1: The chemical structures of thalidomide and related 
thalidomide-derived analogues, lenalidomide and pomalidomide. 
Figure taken from (Fuchs et al., 2014). 
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thalidomide are several thousand times more potent and carry less side effects (Quach et 
al., 2010). As derivatives of thalidomide, they deliver many of the same effects, such as 
inhibiting TNF-α release, increasing T-cell and NK-cell activity, inhibiting angiogenesis 
and tumor growth (Figure 2). Although these cellular effects are commonly observed in 
vitro, until recently, very little was known about IMiDs’ direct mechanisms of action 
(MOA).  Recently, breakthrough discoveries have been made to elucidate IMiD MOA. In 
addition to having prevalent immunomodulatory effects, lenalidomide appears to 
modulate the specificity of a E3-ubiquitin ligase to its substrate, triggering downstream 
degradation of B-cell lymphoid transcription factors critical for B-cell growth, a driving 
factor for plasma cell malignancy (Guirguis et al. 2015). Given IMiDs’ wide capabilities 
observed in vitro, this direct MOA is likely only one of many yet to be discovered. In 
clinical trials, these improved versions of novel IMiDs have made a significant impact in 
extending rates of survival among patients. These drugs are used widely today in the 
treatment for not only multiple myeloma but also related B-cell cancers like 
myelodysplastic syndrome (MDS) (Blum, 2010).  
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With the introduction of novel agents like thalidomide, lenalidomide, 
pomalidomide as well as other cytotoxic agents like proteasome inhibitors (PIs), today 
patients with newly diagnosed multiple myeloma have many treatment options available. 
Patients are usually started on a triple-drug induction regimen that contains combinations 
of novel agents (IMiDs, PIs), dexamethasone, and other chemotherapeutic agents (Table 
Figure 2: A summary of various immunomodulatory effects of thalidomide and 
IMiDs on multiple myeloma (MM) cells, the tumor microenvironment, and on the 
host immune system. Notably, IMiDs boost immune response by stimulating T-cell 
proliferation and response, inhibit angiogenesis, stimulate apoptosis of MM cells, and 
prevent MM cell adhesion to nearby mesenchymal tissue. Figure taken from (Richardson 
et al., 2004). 
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1). Patients, depending on their individual circumstances, are then considered for ASCT 
post induction therapy. In some cases, particularly with older patients diagnosed before 
novel IMiDs were approved, they may have even received ASCT already and require 
salvage chemotherapy with novel IMiDs.  
In patients with relapsed MM, many factors are considered before deciding 
appropriate treatment options, including longest remission time, toxicity concerns from 
previous treatments. Front-line treatment regimens are categorized as IMiD-based, 
Bortezomib-based, or some combination of the two. Commonly used drugs used in 
combination with novel agents include steroids like dexamethasone and prednisone and 
alkylating agents, like Bendamustine. High-dose therapy (HDT) along with ASCT can 
still be considered if patients have shown a previous positive response. Along with 
approved drugs, several drugs are available through clinical trials like carfilzomib, a next-
generation proteasome inhibitor, and monoclonal antibodies elotuzumab and 
daratumumab, which target plasma cell surfaces and cause plasma cell death (Sonneveld 
et al. 2016). 
While significant progress has been made in the past few decades, to this day 
there is no lasting cure for multiple myeloma. This is the reason why it remains 
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imperative that further research be done to improve the efficacy of current treatments or 
develop new pharmacological agents to counter this devastating disease.  
 
 
Table 1: A summary of common treatments for multiple myeloma, dosing regimens, 
mechanism of action, and common side effects. Common IMiDs used are thalidomide, 
lenalidomide, and pomalidomide. Common proteasome inhibtors include bortezomib and 
carfilzomib. Treatment regimens usually combination combinations of either novel agent 
or in combination, along with corticosteroids and other chemotherapeutic drugs. Figure 
taken from (Rajkumar et al., 2016). 
	9 
The Risks of Treating Multiply Myeloma with IMiDs 
 Although the use of IMiDs have provided substantial benefits to patients, median 
survival rates only range from 5 to 7 years after diagnosis and treatment (Srivastava et al., 
2013). Taking IMiDs drugs additionally lead to increased risks for multiple adverse 
effects, like thromboembolism (blood clots), peripheral neuropathy (when using 
thalidomide, but not lenalidomide), increased recurrence of secondary malignancies or 
hematological disorders (Wang et al., 2015). The costs of the lenalidomide treatment are 
also enormous, running more than 60,000 dollars per year in healthcare costs (Goss et al., 
2006). Given these risks and the high cost of using IMiDs, it is important that they be not 
only comprehensively assessed, but also further researched (both in the laboratory and in 
the clinic) so that the best care can be provided to patients with multiple myeloma. 
 
The following thesis will detail the role IMiDs have played in advancing multiple 
myeloma treatment, particularly exploring recently-discovered mechanisms of action and 
clinical implications. 
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SPECIFIC AIMS 
 
Specific aims of the following thesis include: 
1. An in-depth investigation into the published biological mechanisms of IMiDs. 
2. An overview of treatment options for multiple myeloma and examples of several 
large clinical trials highlighting IMiD efficacy and safety. 
3. A discussion on the significant impact IMiDs and other novel agents have made 
in the treatment of multiple myeloma and future directions for the field. 
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PUBLISHED STUDIES 
 
The history of Thalidomide and development of newer analogs 
Thalidomide (alpha-N-phthalimido-glutarimide) is a glutamic acid derivative, 
developed by Chemie-Grunenthal, a German pharmaceutical company, used as an 
antiemetic for pregnant women in the 1950s and 1960s.  It was banned from use in 
Europe and in other countries around the world, because of its horrendous teratogenic 
effects. Nearly 10,000 children around the world suffered severe birth defects 
(Vargesson, 2015). Due to swift action of the Food and Drug Administration (FDA) in 
the United States, thalidomide was, thankfully, banned from the market. The thalidomide 
disaster represented a turning point in pharmaceutical history, for it changed the way 
drugs were tested and approved, especially in the United States.  
Structurally, thalidomide is a two-ringed compound, consisting of a glutarimide 
and pthalimide ring (Vargesson, 2015; Figure 1). Because of its chiral carbon, it exists as 
an unstable enantiomer in bodily fluids, rapidly switches between two states (Rehman et 
al., 2011). One state is known to be a sedative, which helps relieve morning sickness 
symptoms, while the other state is teratogenic (Vargesson, 2015; Rehman et al., 2011). 
The compound was sold as a racemic mixture, which explains why its toxic effects were 
not immediately realized (Franks et al., 2004).  
Despite its obvious toxic effects, it was eventually found to be effective in the 
treatment of leprosy, which is an inflammatory disease due to its potent anti-
inflammatory abilities, namely because of its ability to lower serum TNF-α through 
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inhibition of cytokine release by monocytes (Sampaio et al., 1991). Eventually its anti-
angiogenic and anti-inflammatory properties were further researched in vitro, propelling 
a wide search by Celgene Corporation to develop more potent, less toxic analogs, 
collectively called immunomodulatory drugs. 
Immunomodulatory drugs or IMiDs are a class of drugs derived from thalidomide 
that possess a number of properties that are able to combat multiple myeloma and similar 
cancers of the blood. IMiDs have been shown in vitro to have multiple anti-angiogenic, 
anti-inflammatory, and anti-proliferative effects (Figure 2). Their most crucial function 
appears to be their immune-modulating capabilities, through co-stimulation of T and 
natural killer (NK) cells (D’Amato et al., 1994, Haslett et al., 1998), thereby improving 
patients’ immune capacity to combat tumors. Although their direct mechanism of action 
is not well understood, this section seeks to explore the numerous effects IMiDs, namely 
thalidomide, lenalidomide, and pomalidomide, have on malignant cells. 
 
Immune modulation 
Myeloma cells are able to evade the immune system because the immune system 
is somehow impaired in its ability to detect and combat malignant cells. This “tolerance” 
of myeloma cells allows cancer cells to survive through various mechanisms. Malignant 
cells produce their own cytokines, like transforming growth factor beta (TGF-β), 
interleukin 10 (IL-10), Interleukin-6 (IL-6), and vascular endothelial growth factor 
(VEGF), all factors that suppress B and T-lymphocyte activation (Quach et al., 2010), 
especially T-cell co-stimulation through dendritic cells (DCs). This protective mechanism 
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essentially depresses the body’s immune system, affecting its abilities to combat tumors. 
IMiDs aid the immune system through several activities that enhance the body’s 
adaptive and innate immune response, through T-cell co-stimulation and NK-cell 
activation. 
 
T cell co-stimulation 
T-cells are activated by antigen presenting cells (APCs), most commonly 
macrophages, B-cells, and dendritic cells (DCs). APCs bear major histocompatibility 
complex (MHC) receptor proteins on their cell surfaces, which are able to capture and 
present antigens to T-cells (Smith-Garvin et al., 2009). T-cells are activated through 
various mechanisms. APCs present antigen to both CD4+ (helper) and CD8+ (cytotoxic) 
T-cells. Usually this activation requires a secondary costimulatory signal that activates T-
cells in conjunction with antigen presentation. Common costimulatory pathways involve 
APC-expressed B7-1 (CD80) and B7-2 (CD86) molecules binding to CD28, a 
constitutively expressed receptor on most CD4+ and CD8+ T-cells (Sharpe et al, 2006). 
When APCs process antigen, B7-1 and B7-2 expression is upregulated, providing the 
required secondary signal for T-cell activation. Adding thalidomide and other IMiDs in 
vitro allows T-cells to activate without this secondary signal (Davies et al., 2001). IMiDs, 
in addition, do not preferentially stimulate a T-cell subtype; CD4+ and CD8+ T-cells are 
stimulated equally (Davies et al., 2001).  
In studies where T-cells were selectively purified from human peripheral blood 
mononuclear cells (PBMCs), thalidomide increased proliferation of T-cells and 
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production of Type 1 helper T-cell (Th1) cytokines, interleukin-2 (IL-2) and interferon 
gamma (IFN-γ), when compared to control (Davies et al., 2001). Increased secretion of 
IL-2 notably promotes T-cell differentiation into effector T-cells and memory T-cells, 
further facilitating the body’s adaptive immune response (Boyman et al., 2012). IFN-γ, 
on the other hand has many crucial immunoregulatory and anti-tumor properties, among 
them promoting NK-cell activity and further Th1 differentiation through upregulation of 
the T-box (T-bet) transcription factors through a positive feedback loop (Raphael et al., 
2015). Th1 cells selectively stimulate cytotoxic CD8+ T-cells. In contrast, thalidomide 
suppresses release of Type 2 helper T cell (Th2) cytokines, such as Interleukin 4 (IL-4), 
IL-10 (Haslett et al., 1998). Expression of these molecules is downregulated, suppressing 
the body’s humoral response. Thus, with administration of IMiDs, the adaptive immune 
response is significantly amplified to target growing malignancies.  
The precise mechanisms by which IMiDs enhance T-cell proliferation and activity 
is unknown, although several mechanisms have been proposed. Studies in the literature 
definitely show that IMiDs are able to promote IL-2 release through increasing the 
transcriptional activity of activated protein 1 (AP-1) (Payvandi et al., 2005; Schafer et al., 
2003; Figure 3). Enhancing production of IL-2 not only increases T-cell differentiation 
but also feeds into pathways activating the innate immune system, notably NK-cells. 
Lenalidomide, additionally, has been shown cause increased tyrosine phosphorylation of 
CD28 receptor, in addition to MHC activation (Hiyashi et al., 2005; Figure 3), which 
enhances downstream production of IL-2 and other cytokines, cell-survival genes, and 
cellular metabolism (Sharpe et al., 2006). 
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Figure 3: Proposed pathways by which lenalidomide upregulates T-cell signaling 
pathways. Lenalidomide increases CD28 phosphorylation that feeds into multiple major 
cell signaling pathways, like PI3K/Akt and Ras pathways that eventually upregulate AP-1 
and NF-kB and IL-2 expression and pro-inflammatory cytokines. The mechanisms by 
which this happens is still unknown. Figure taken from (McDaniel et al., 2012).  
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Thalidomide’s analogs, lenalidomide and pomalidomide, are nearly 50-2000 
times more potent then thalidomide at promoting T cell production through released of T-
cell IL-2 and IFN-γ (Davies et al., 2001). In in vitro settings, pomalidomide is even more 
potent than lenalidomide, which is a reason why it is administered at lower doses (Quach 
et al., 2010). 
 
Increased NKT cell activity and NK cell activity through antibody-dependent cellular 
cytotoxicity (ADCC) 
IMiDs are able to boost the innate immune system by stimulating NK-cell and 
NKT cell activity (Davies et al., 2001). NK-cells are a type of lymphocyte, descending 
from the same lymphoid progenitor cells that eventually forms B and T cells, that possess 
important anti-viral properties, help combat tumor formation, and are non-specific in that 
they do not require MHC-class markers for activation (Vivier et al., 2012). NKT cells are 
T-lymphocytes that have similar effects as NK cells. They bear NK surface markers and 
have anti-tumor effects, like inducing direct cytotoxicity to malignant cells (Quach et al., 
2010). In addition, NKT cells produce IFN-γ  and are able to activate other NK cells and 
DCs (Schoenborn et al., 2007). 
NKT cells carry MHC-1-like CD1d receptors on their surfaces that recognizes 
glycolipid antigens (Schoenborn et al., 2007). When activated by DCs bearing a 
recognized antigen like α-GalCer NKT cells are able to greatly expand in numbers, thus 
amplifying their immune effects (Vivier et al., 2012). Lenalidomide, notably, increases 
not only NKT expansion triggered by DCs, but also increases NKT secretion of IFN-γ, 
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which is important for cytotoxic T-cell activation (Fujii et al., 2003). This is an example 
where IMiDs are able to activate both arms of the immune system by targeting expansion 
of one cell type that releases factors that expand cell numbers of the other arm. NKT 
expansion is also partially the reason IMiDs are able to enhance NK-cell activation and 
proliferation, through release of IFN-γ, which enhances cell death in multiple myeloma 
cell lines and primary cancer cells obtained from patients (Carnaud et al., 1999) 
NK cells, like NKT cells, have important anti-tumor and anti-viral effects. In 
addition to directly killing cells through antibody-dependent cellular cytotoxicity 
(ADCC), NK cells also produce cytokines like IFN-γ that recruit T-cells and other DCs to 
respond to antibody-coated target cells (Schoenburn et al., 2007). ADCC is a process in 
which immunoglobulin proteins specific for tumor antigens activate the Fc-γ receptors on 
NK cell (Muntasell et al., 2017). When the Fc-γ receptor is cross-linked, cell cytotoxicity 
is triggered through release of enzymes like perforin, granzyme B and pro-inflammatory 
cytokines (Muntasell et al., 2017). NK-cells can also trigger tumor cell apoptosis through 
pathways facilitated by death ligands like the Fas ligand (FasL) and TNF-related 
apoptosis-inducing ligand (TRAIL) expressed on cell surfaces (Quach et al., 2010). 
IMiDs in vitro are able to induce IL-2-primed human PBMCs to cause increased MM-
cell lysis, suggesting IMiDs’ ability to stimulate NK-cell number and function. (Davies et 
al., 2001). Lenalidomide and pomalidomide, notably, in the presence of IL-2, increase 
NK cell expression of the FasL ligand and granzyme B, thereby enhancing cell’s natural 
ADCC capabilities (Wu et al., 2008).  
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Inhibition of T-regulatory cells  
 T-regulatory (T-reg) cells suppress T-cell activity, which normally prevents 
immune systems from being continuously active or overactive. In the presence of tumors 
however, immune suppression can be problematic. IMiDs have been shown to decrease 
the number of T-reg cells in a T cell population extracted from PBMCs, due to 
downregulation of a forkhead box P3 (FOXP3) transcription factor, which drives T-reg 
activity (Galustian et al., 2009). However, these effects were mostly observed in vitro. 
Clinically, IMiDs’ effect on T-reg cells is not well understood, as some studies reported 
near normal T-reg numbers in multiple myeloma patients who were receiving IMiD-
based treatments (Quach et al., 2010). This is an example in which the benefits of IMiDs 
seen in vitro are not so easily translated when used in the clinic, as each patient’s tumor 
and immune capabilities are different. It is possible that IMiDs effects are muted when 
considering the multiple factors playing into a patient’s disease progression. 
 
Tumor Microenvironment Interactions 
Multiple myeloma is a disease in which malignant plasma cells grow and divide 
uncontrollably in the bone marrow. Malignant cells are highly dependent on tumor 
microenvironment. Due to genetic abnormalities, these cancerous cells are able to grow 
and spread because they are able to effectively evade a patient’s anti-tumor immune 
response. Plasma cell (PC) adhesion to the bone marrow stromal cells is critical to their 
survival and is required for growth. Malignant PCs are anchored to the bone marrow 
stromal cells (BMSCs) through a variety of interactions between the different cellular 
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surfaces. Malignant PCs express the CXC-chemokine receptor type 4 (CXCR4), which 
partners with stromal-derived factor-1 (SDF-1) on BMSCs (Hideshima et al., 2002; 
Gazitt et al., 2004). This interaction facilitates further PC-BMSC interactions by 
increasing plasma cell expression of adhesion molecules on cell surface like very late 
antigen 4 (VLA-4) and lymphocyte function-associated antigen 1 (LFA-1), which bind to 
vascular cell adhesion protein 1 (VCAM-1) and intracellular adhesion molecule 1 
(ICAM-1) molecules on BMSCs (Wang et al., 2007). Plasma cells also adhere to the 
local extracellular matrix proteins like collagen and fibronectin through proteins like 
syndecan-1 (CD138) and VLA-4 (Bianchi et al., 2012; Kawano et al., 2012). Plasma cells 
are securely attached, a signaling cycle occurs in which the transcription factor, nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) is activated, furthering 
production of more cytokines and adhesion molecules (Bianchi et al., 2012).. 
NF-κB, notably, is a transcription factor that promotes growth and inhibits 
apoptosis by upregulating critical intracellular adhesion molecules. NF-κB is important 
for normal cells; however in malignant cells, constant NF-κB activation becomes 
problematic. Along with intracellular adhesion molecules, many other cytokines are 
produced, including vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor (β-FGF), TGF-β, TNF-α, IL-10, and IL-6, which all promote plasma cell growth 
and survival (Chauhan et al., 1996). This begins essentially a positive feedback loop 
where transcription of growth factors and cytokines enhance further cytokine and growth 
factor release (notably IL-6, which is important for B-cell and plasma cell development). 
The binding of these various cytokines triggers multiple cell-signaling pathways like the 
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mitogen-activated protein kinase (MAPK) and PI3K/Akt pathways that inhibit cell 
apoptosis (Hideshima et al., 2002). These global signaling pathways have widespread 
effects on the cell, triggering a cascade of downstream events that not only result in 
increased expression of anti-apoptotic molecules, but also promote even more cytokine 
and growth factor release. Given that the interaction between malignant cells and their 
microenvironment is so critical to tumor survival, it has been hypothesized that somehow 
disrupting that interaction could stop disease progression.  
IMiDs originally were found to be effective because of its ability to inhibit the 
release of TNF-α (Sampaio et al., 1991), a critical cytokine involved in many immune 
system pathways. Years of research since this discovery have sought to decipher the 
multiple anti-inflammatory, anti-angiogenic effects IMiDs have on cancerous plasma 
cells, notably their ability to downregulate cytokines and adhesion molecules critical to 
tumor cell survival. 
 
Anti-angiogenic properties 
Angiogenesis is the process by which vascular networks grow to feed and nourish 
a growing tissue. As one of the primary hallmarks of cancer, angiogenesis is an important 
way malignant cells are able to utilize the body’s resources to proliferate. Although there 
have been drugs tested in clinical trials that inhibit release of angiogenic factors like 
VEGF, the impact of this treatment strategy remains unclear. All IMiDs have some anti-
angiogenic properties; however, thalidomide predominantly is the IMiD that has the 
highest activity. The newer analogs lenalidomide, and pomalidomide have more potent 
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immunomodulatory effects (Quach et al., 2010), but lower anti-angiogenic properties. 
Through modulation of chemotactic factors like VEGF, β-FGF, TNF-α that 
promote migration of endothelial cells, thalidomide is able to inhibit growth of vascular 
network formation, particularly in in vitro model systems (Dredge et al., 2002). 
Thalidomide is able to inhibit angiogenesis induced by β-FGF in vivo, although the 
mechanism by which this happens is unclear (D’Amato et al., 1994). Thalidomide does 
not directly inhibit endothelial cell proliferation (Dredge et al., 2002). However, this 
effect is not obvious clinically, as microvascular density as well as plasma VEGF levels 
are not always reduced in patients with multiple myeloma (Mileshkin et al., 2007).  
VEGF and β-FGF are also signaling molecules that feed into the prominent 
signaling pathways, like the P13K/Akt pathway. Thus, administration of IMiDs and 
subsequent inhibition of these molecules seem to have both anti-angiogenic and pro-
apoptotic effects. Overall, although the evidence is not clear that IMiDs’ anti-angiogenic 
effects are able to severely impact cellular growth, it is likely to carry some effect, 
especially when most of the molecules implicated play important roles in other cellular 
pathways. 
 
Anti-inflammatory properties 
Thalidomide was first proposed to be an anti-inflammatory drug. Inflammation is 
a necessary process by which the body deals with tissue injury and is facilitated by a wide 
variety of cytokines and prostaglandins. Cytochrome c oxidase 2 (COX2) is an enzyme 
that produces the many pro-inflammatory prostaglandins that cause the painful symptoms 
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of inflammatory conditions like rheumatoid arthritis and Crohn’s disease. Because COX2 
is implicated in the pathogenesis of many cancers, it is not surprising that inhibiting 
COX2 has been shown to induce apoptosis in MM cell lines (Zhang et al., 2009). All 
IMiDs inhibit COX2 expression by decreasing COX2 mRNA translation in a dose-
dependent manner, subsequently reducing the amount of prostaglandins that facilitate the 
more harmful inflammatory responses (Payvandi et al., 2004).  
Apart from inhibiting important inflammatory enzymes, thalidomide also has 
more wide-spread anti-inflammatory effects. Notably, it is able to downregulate TNF-α  
production from LPS-stimulated monocytes and inhibit other inflammatory proteins, like 
macrophage inflammatory protein-alpha. Lenalidomide and pomalidomide are several 
thousand times more potent than thalidomide in their TNF-α reducing capabilities 
(Quach et al., 2010).  
 
Downregulation of cell surface adhesion molecules and TNF-α  
As mentioned, all IMiDs inhibit the release of TNF-α. Through a positive 
feedback loop, TNF-α is a trigger molecule for the expression of many cell surface 
adhesion molecules that facilitate interactions between BMSC and the PC. Molecules like 
LFA-1, ICAM-1, VCAM-1, VLA-4 are all subsequently downregulated due to lack of 
TNF-α (Geitz et al., 1995). This positive feedback loop is important for cellular survival 
and decreases plasma cell adherence to the BMSC, which further downregulates release 
of cytokines by the BMSC that promote cell survival. 
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Anti-tumor Effects  
 
CDK inhibition 
 IMiDs have been shown to have anti-proliferative effects on primary human MM 
cells derived from patients (Bartlett et al., 2004). A separate study by Verhelle et al. 
confirmed these findings in additional cell lines. The group tested IMiDs on 
hematopoietic cancer cell lines (Namalwa, LP-1, and U266) and found that the 
expression of the cyclin dependent kinase (CDK) inhibitor, p21WAF-1, was upregulated, 
correlating with simultaneous decrease in CDK2, 4, 6 proteins leading to cell cycle arrest 
(Verhelle et al., 2007).  
 
Cas 3,8,9 inhibition 
One hallmark of cancer is failure of malignant cells to undergo apoptosis. 
Apoptosis is a complex pathway, triggered by signaling molecules, that facilitates natural 
cell death without activating other inflammatory branches of the immune system. It is 
known that IMiDs inhibit the activity of NF-κΒ, a transcription factor that also 
upregulates expression of many adhesion molecules. Inhibiting NF-κΒ, also has the 
additional benefit of decreasing expression of anti-apoptotic proteins like cellular 
inhibitor of apoptosis (cIAPs) (Chu et al., 1997) and FLICE-inhibitory protein (FLIP) 
(Kreuz et al., 2001), which inhibit Caspase 8 (Cas 8, an upstream caspase) effectively 
turning off the inhibitory proteins that prevent apoptosis from occurring. In the cell, 
apoptosis occurs through a activation cascade of multiple caspase proteins. Cas 8 and Cas 
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9 are two proteins that independently activate later caspases (Cas 3,6,7) in the apoptosis 
pathway (Quach et al., 2010). IMiDs primarily activate Cas 8 through separate 
mechanisms, through directly activating the enzyme through some unknown pathway or 
by inhibiting NF-κΒ, which reduces Cas 8 suppressor molecules (Mitsiades et al., 2002; 
Figure 4). Cas 8 can be activated by cytokines like TNF-α or common death ligands, like 
FasL and TRAIL. Cas 9 can be activated using other drugs on market commonly dosed in 
combination with IMiDs, notably Dexamethasone and Bortezomib, which may account 
for the greater efficacy seen with combination therapies in the clinic (Figure 4).  
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Figure 4: IMiDs and other novel agents are able to activate cellular apoptotic 
pathways. IMiDs are able to activate apoptotic pathways through multiple 
pathways, through inhibition of NF-kB which decreases anti-apoptotic molecules 
and subsequently Cas8. Bortezomib is able to cause Cas9 activation and work 
synergistically with IMiDs to enhance cellular apoptosis. Figure taken from (Quach 
et al., 2010). 
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Recently Discovered Mechanisms: Direct Effects of IMiDs on cellular processes 
Up until recently, no direct mechanism has ever been discovered for IMiDs. 
Recently, in several ground-breaking publications, one prominent mechanism of action 
for IMiDs was discovered. Lenalidomide and all its related analogs promote cellular 
ubiquitination and protein degradation by modulating the substrate specificity of the 
cullin 4-RING (CRL4) E3 ubiquitin ligase. Recent studies have shown that IMiDs, 
notably lenalidomide, bind cereblon (CRBN), a substrate receptor for the CRL4 E3 
ubiquitin ligase (Lopez-Girona et al., 2012). In fact, it was this initial finding that 
thalidomide binds CRBN-DDB1 that suggests to thalidomide’s teratogenicity, indicating 
for the first time the direct effect IMiDs have on cells (Ito et al., 2010; Lindner et al., 
2016). The CRL4 E3 ubiquitin ligase is a complex of proteins consisting the cullin ring 4 
ligase (CUL4A) and two other proteins, damaged DNA binding protein 1 (DDB1) and 
RING finger protein regulator of cullins (ROC1) (Guirguis et al., 2015; Figure 5). CRBN 
is an essentially an attached protein adaptor that aids in ubiquitination of specific protein 
substrates that are later polyubiquitinated and degraded. IMiDs increase CRBN binding 
to its substrates, leading to increases in protein degradation, affecting processes 
downstream. This interaction is highly specific and if CRBN is inactivated, all 
downstream effects of IMiDs are abrogated (Zhu et al., 2011). This interaction makes 
sense structurally, as IMiDs glutarimide ring sits in the substrate binding pocket of 
CRBN (Fischer et al., 2014). Given their molecular specificity, it is possible that future 
IMiD structures can be modified to further enhance this binding.  
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Through mass spectrometry studies and luciferase-based screens characterizing 
lenalidomide-induced changes in ubiquitinated protein, two proteins were identified that 
were selectively degraded, Ikaros (IKZF1) and Aiolos (IKZF3) (Kronke et al., 2014; Lu 
et al., 2014). As transcription factors vital in B and T cell biology, IKZF1 and IKZF3 are 
important for lymphocyte terminal differentiation (Guirguis et al., 2015). IKZF1 is 
expressed throughout lymphoid development while IKZF3 is expressed in the later 
phases when B and T-cells mature (Shaffer et al., 2008). IKZF1 and IKZF3 are important 
Figure 5: Components of CRL4 
E3 Ubiquitin Ligase. IMiDs bind 
to CRBN, an adaptor that is part of 
the ubiquitin ligase complex, 
trigging increased proteasomal 
degradation of downstream 
transcription factors. Figure taken 
from (Guirguis et al., 2015). 
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regulatory proteins, as studies have shown that mutations or gene knockouts of these two 
proteins cause widespread downstream effects. IKZF1 binds the promotor of interferon 
regulatory factor 4 (IRF4) (Jin et al., 2016), a master regulator of in aberrant genes in 
malignant myeloma cells, including the positive feedback loop containing the notable 
oncogene MYC and other survival genes (Fink et al., 2015). Mutations in IKZF1 
essentially depletes the immune system of mature B cells, NK cells, and properly-
differentiated T-cells (Guirguis et al., 2015). IKZF3, notably, is essential for plasma cell 
development and its overexpression could be an explanation for plasma cell malignancy. 
In T-cells, IKZF3 also acts as a transcriptional repressor of the IL-2 gene promotor, 
which essentially suppresses T-cell activation (Gandhi et al., 2013) as well as NK and 
NKT cell activity (Fink et al., 2015).  
When lenalidomide binds specifically to CRBN, IKZF1 and IKZF3 binding to 
CRBN and proteasomal degradation of these transcription factors is enhanced. With 
IMiD-induced degradation of IKZF1, IRF-4 and subsequently MYC is downregulated, 
causing direct MM cell death (Kronke et al., 2014). Lenalidomide-induced depletion of 
IKZF3, in addition, removes the IL-2 inhibition in T-cells, causing increased IL-2 release 
and further T-cell activation (Kronke et al., 2014; Gandhi et al., 2013). Indeed, it is the 
discovery of this novel mechanism that could explain not only thalidomide’s teratogenic 
effects, but IMiDs beneficial impact on slowing cancer cell progression. Further research 
has demonstrated that IMiDs could be beneficial for use in other related B-cell 
malignancies, particularly myelodysplastic syndrome (MDS) (Kronke et al., 2015).  
The finding that lenalidomide decreases expression of IKZF1 and IKZF3 by 
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increasing its degradation has proven to be a useful biomarker clinically. Biomarkers are 
important to track during treatment, as they give indications of drug efficacy or toxicity, 
depending on what the biomarker is. Previously, no useful biomarker for multiple 
myeloma was known to exist. CRBN expression levels have been explored as a 
predictive biomarker for IMiD resistance. Patients with low CRBN levels have been 
shown to respond poorly to IMiD treatment (Schuster et al., 2014). IKZF3 is another 
potential candidate, as IKZF3 degradation is detectable in the peripheral T-cells of 
healthy subjects dosed with IMiDs (Gandhi et al., 2013); however, few publications have 
demonstrated this MM patients. However, recently a paper published by Bolomsky et al. 
suggests that IKZF1 proteins expressed in the bone marrow environment could be a 
potential candidate. They demonstrated that bone marrow (BM) mononuclear cells 
extracted from MM patients under IMiD-based regimens could be analyzed for gene 
expression of major proteins affected by IMiD treatment. Interestingly, increased 
expression of CRBN and IKZF1, but not IKZF3, along with other CRBN-IMiD targets, 
like IRF-4, correlated significantly with increased response to treatment (Bolomsky et al., 
2016). IKZF1 expression, notably, was elevated in many cellular subsets of the bone 
marrow cell environment, such as total BM mononuclear cells, CD19+ B-cells, 
CD3+CD8+ T cells, monocytes in patients who had increased overall survival (OS), 
suggesting its predictive power in the clinic (Bolomsky et al., 2016). High IKZF1 in the 
bone marrow environment of these patients could reflect greater anti-tumor and 
immunomodulatory responses due to IMiD treatment. It must be noted that IKZF1 
protein levels in actual multiple myeloma cells showed no predictive correlation.  
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Likely, more research needs to be done to elucidate alternative mechanisms of 
action for better understanding of mechanism is what will lead to more potent therapies in 
the future. 
 
Clinical impact of IMiD Regimens for multiple myeloma 
The introduction of IMiDs into the standardized methods of care for multiple 
myeloma has made a large impact on patients. Although the in vitro data has sufficiently 
shown the benefits of IMiDs, those effects are not so easily translated when it comes to 
treating patients. This points to the importance of randomized clinical trials to 
demonstrate experimentally, the true benefits of novel therapeutics. For multiple 
myeloma, many novel agents have been used individually or in combination with each 
other: thalidomide, lenalidomide, bortezomib, and dexamethasone, melphalan, and 
prednisone to improve progression free survival (PFS) and overall survival (OS), two 
end-points that most clinical publications focus on.  
 
Overview of Treatment Options for Multiple Myeloma  
 Due to an increased understanding of disease biology and the subsequent 
development of novel agents, treatment of multiple myeloma has undoubtedly rapidly 
advanced, especially when novel agents like IMiDs and proteasome inhibitors (PIs) were 
introduced to the market. Today, multiple myeloma patients have much more options and 
access to drug combinations that, clinically, demonstrate greater efficacy than 
conventional chemotherapy treatment. Even more recent Phase III randomized-clinical 
trials (RCTs), published in the past 5 years, have demonstrated new combinations with 
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second and third generation drugs that result in deeper responses and subsequently 
prolonged PFS and OS.  
In both transplant-eligible and non-eligible patients with multiple myeloma, the 
initial goal of therapy is to achieve a maximal response with as minimal toxicity as 
possible (Lonial et al., 2015). The aim is to treat the disease as aggressively as possibly 
without triggering serious adverse reactions. For patients with relapsed multiple 
myeloma, the goals remain similar, however different regimens may be utilized, due to 
developed patient resistance to certain treatments. Choosing the best treatment, therefore, 
requires consideration of many factors including observations of cancer progression upon 
initial diagnosis, patient history, prior treatments, eligibility for autologous stem cell 
transplantation (ASCT), and general patient-related factors (Lonial et al., 2015; Figure 
6).  
Induction therapy is the first phase of treatment for multiple myeloma and usually 
lasts for several months. The aim of induction therapy is to reduce the number of 
malignant plasma cells in the bone marrow and the proteins that the plasma cells produce 
to achieve a deep initial response. It can be prescribed as a combination of novel agents 
and corticosteroids, depending on patients’ individual circumstances. 
For transplant eligible patients, after initial induction therapy and initial remission 
is achieved, patients can be considered for ASCT. ASCT is a risky procedure where a 
patient’s own stem cells in the blood stream (called peripheral blood stem cells, PBSCs) 
are harvested and then transplanted back into patients, post high-dose chemotherapy 
(HDT) Once transplanted, PBSCs allow bone marrow to regenerate and produce more 
	32 
blood cells. Post-ASCT, patients are usually put on maintenance therapies that help 
prolong remission, usually with lenalidomide or thalidomide. If patients relapse, a second 
ASCT can be considered and alternate combination regimens are considered (Grethlein et 
al., 2016). 
For transplant ineligible patients, they are immediately put on an aggressive 
novel-agent combination regimen containing novel agents, melphalan, or corticosteroids. 
Proteasome inhibitors like bortezomib and carfilzomib are commonly used in 
combination with steroids or with IMiDs. They work by inhibiting proteasome complexes 
in cells that break down proteins that regulate the cell cycle. Corticosteroids are often 
prescribed as well. Clinically, they seem to work synergistically with novel agents to help 
patients achieve a deeper response. 
Alternative therapies involve chemotherapeutic drugs like doxorubicin and 
vincristine and are considered if patients do not respond to initial therapies. However, 
chemotherapy drugs are highly toxic and cause a number of serious side-effects. Patients 
are also at risk for infections due to a depressed immune system and can also suffer 
permanent damage from prolonged exposure to chemotherapy regimens.  
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Figure 6:	A summary of clinician’s process of determining best method of care 
for multiple myeloma patients.	ASCT, autologous stem cell transplant; CRAB, 
calcium (hypercalcemia), renal (renal insufficiency), anemia, bone (bone lesions); CR, 
complete response; CyBorD, bortezomib-cyclophosphamide-dexamethasone; FLC, free 
light chains; IRd, ixazomib-lenalidomide-dexamethasone; KRd, carfilzomib-lenalidomide-
dexamethasone; MP, melphalan-prednisone; MPT, melphalan-prednisone-thalidomide; Rd, 
lenalidomide-dexamethasone; RVd, lenalidomide-bortezomib-dexamethasone; Vd, 
bortezomib-dexamethasone; VGPR, very good partial response; VMP, bortezomib-
melphalan- prednisone; VRD, bortezomib-lenalidomide-dexamethasone; VTD, 
bortezomib-thalidomide-dexamethasone. Figure taken from (Raza et al., 2017). 	
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Given the abundance of treatment options available for multiple myeloma 
patients, it is natural to wonder which treatment provides the most benefits in terms of 
longer disease remission, PFS and higher OS. The following section outlines some of the 
clinical data obtained from notable clinical trials and major conclusions from several 
large meta-analysis publications that use high-power statistical analysis to look at data 
from multiple RCTs. Although there is a wide array of clinical data on non-IMiD drugs, 
this section will focus mainly on studies using lenalidomide or thalidomide individually 
or in combination with other drugs. Because bortezomib-based regimens are as prevalent 
as IMiD-based ones, studies comparing bortezomib to other treatment regimens will also 
be briefly explored. Summaries of these various studies are also provided in the 
Appendix (Tables 2-4).  
 
 
Meta-analyses performed comparing IMiD versus Bortezomib-based regimens 
Looking at clinical data, post-FDA approval, is important because these results 
are acquired from independent researchers, usually unassociated with the company that 
develops the drug. Currently in the literature, there are hundreds of large randomized 
clinical trials (RCTs) conducted comparing different treatment regimens either to each 
other or to placebo. Several groups have also published meta-analyses of several RCTs to 
normalize for different treatment groups and experimental set-ups in order to utilize the 
clinical data available to make appropriate comparisons. Although many studies look at 
the effect of one regimen versus another, there were relatively few meta-analyses in the 
literature that compared lenalidomide, thalidomide and bortezomib-based regimens.  
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One such meta-analysis was performed by Wang et al. The group analyzed over 
17 RCTs, pooling the clinical data from over 6,000 patients, involving bortezomib, 
lenalidomide, and thalidomide, comparing the efficacy and safety of each treatment. The 
group looked at different parameters like complete response (CR), progression-free 
survival (PFS), overall survival (OS), and prevalence of adverse effects (AEs), compared 
the results between patients who had received ASCT and patients that did not. Overall, 
their meta-analysis showed that all agent-based regimens showed greater PFS regardless 
of receiving ASCT (Wang et al., 2016). OS was only improved in the bortezomib and 
thalidomide treatment groups that had not received ASCT (Wang et al., 2016). The study 
recommended that although novel agent treatments containing IMiD and/or proteasome 
inhibitors (PIs) were clinically beneficial, the AE prevalence was something to take into 
account. 
Zou et al. similarly concluded from similar meta-analysis, looking at 10 RCTs and 
4,534 patients that lenalidomide increases PFS but not OS. The addition of lenalidomide 
had no impact on survival (Zou et al., 2013). The addition of bortezomib to first-line 
therapy, on the other hand significantly prolonged OS (Zou et al., 2013). Both 
lenalidomide and bortezomib consistently improved PFS compared with therapies that 
did not contain novel agents; however, lenalidomide was associated with a higher 
prevalence of AEs (Zou et al., 2013).  
Sonneveld et al. performed a meta-analysis of multiple Phase III RCTs that 
compared the efficacy of bortezomib-based induction therapies versus non-bortezomib-
based therapies in newly diagnosed MM patients who had not undergone ASCT. From 
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data obtained from 1,572 patients, the group concluded that bortezomib-based therapies 
induction therapies were superior to non-bortezomib based therapies. Median PFS was 
35.9 months in the bortezomib-regimen arms and the 3-year OS was 79.7%, compared to 
the PFS of 28.6 months and 3-year OS of 74.7% observed for other induction treatments, 
namely the vincristine-doxorubicin-dexamethasone (VAD) and thalidomide-
dexamethasone combination therapies (Sonneveld et al., 2013). 
Of all the meta-analyses searched, few actually compared RCTs that tested 
bortezomib in combination with thalidomide or lenalidomide. Wang et al. analyzed 14 
RCTs, pooling results from 5,379 newly-diagnosed or previously untreated MM patients 
and demonstrated that between 3 bortezomib-based regimens – bortezomib-thalidomide 
(VT), bortezomib-lenalidomide (VR), and bortezomib-doxorubicin (VD), the VT 
regimen had increased CR and overall response rates (ORR) but not PFS and OS (Wang 
et al., 2014). The VD regimen showed an improved CR with little difference in PFS, OS, 
ORR compared to other treatment groups (Wang et al., 2014). In contrast, the VR 
regimen had longer PFS and OS but showed no significant difference in the other end-
points analyzed (Wang et al., 2014).  
A smaller meta-analysis was performed by a different group analyzing efficacy 
and safety of bortezomib-IMiD combination treatments versus treatments of bortezomib 
or IMiDs in separate regimens. Wang et al., showed data from 1,200 newly diagnosed 
MM patients and concluded that bortezomib-IMiD induction therapies increased rates of 
CR without increased risk of major Grade 3 or 4 AEs (Wang et al., 2012). 
From the meta-analyses that manage to compare bortezomib-based regimens with 
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IMiD-based ones, it remains unclear which treatment is more beneficial, although more 
evidence points to regimens with bortezomib being marginally more effective. However 
very little RCTs are comprehensive enough to systematically compare all these treatment 
combinations commonly used today. Meta-analyses do not tell the whole story however, 
so in some cases it is useful to look at individual phase III RCTs to see benefits of IMiDs. 
 
IMiD-based regimens in transplant setting  
Autologous stem cell transplantation (ASCT) is a common procedure multiple 
myeloma patients go through. There is significant data in the literature showing that 
combination of induction therapy with ASCT and maintenance therapies containing 
various novel agents result in the best improvement in PFS, OS, and quality of life (Raza 
et al., 2017).  
Although there is some debate to which novel agent combination is the most 
beneficial, there is substantial evidence that combination therapies work better than drugs 
administered individually. One such example is shown by the phase III RCT published by 
Stewart et al.; the group tested effects of thalidomide-prednisone maintenance therapy in 
MM patients, post-ASCT, compared to melphalan treatment alone. They concluded that 
the thalidomide treatment, post-ASCT, improved PFS, but no differences in OS were 
observed at 4 years (Stewart et al., 2012). Although thalidomide treatment improved 
duration of disease control, a significant number of patients reported side effects that 
impacted their quality of life (Stewart et al., 2012). Given thalidomide’s toxicity profile, 
it is unsurprising that it seems to be the less well tolerated than lenalidomide or 
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pomalidomide, analogs that have demonstrated to be less toxic.  
Cornell et al. also looked at the effects of modern doublet or triplet induction 
therapies containing combinations of lenalidomide, bortezomib, cyclophosphamide, and 
dexamethasone post-ASCT and concluded that PFS and OS were all similar regardless of 
which induction regimen was chosen (Cornell et al., 2017). In patients able to receive 
ASCT within 12 months of receiving initial induction therapy, PFS was increased 
compared to those who had not received therapy post-ASCT (Cornell et al., 2017).  
Palumbo et al. also looked at the effect different maintenance therapies with or 
without ASCT had on PFS in a phase III RCT. They assigned more than 500 patients to 
two head-on-head comparisons: 1) high-dose melphalan plus ASCT versus melphalan-
prednisone-lenalidomide (MPR) consolidation therapy post-induction treatment and 2) 
lenalidomide maintenance therapy versus a no maintenance therapy. They concluded that 
high dose melphalan plus ASCT significantly prolonged PFS and OS compared to 
patients who undergo MPR maintenance therapy (Palumbo et al., 2014). The melphalan 
plus ASCT group had a PFS of 43 months vs. 22.4 months observed in MPR and after 4 
years, the OS was 81.6% compared to 65.3% in the MPR arm (Palumbo et al., 2014). 
These conclusions support the idea that ASCTs are still superior to robust combination 
therapies and are still necessary parts of MM treatment, if patients are eligible.  
 
IMiD-based maintenance regimens in transplant setting 
Post-ASCT procedures, MM patients are put on maintenance therapies that 
prolong disease remission for as long as possible until disease relapses. As shown by 
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many RCTs published in the past 5 years, patients on IMiD regimens show significantly 
longer PFS. OS, however, it not necessarily increased, especially when at the 3 or 4-year 
range.  
In the same study discussed previously, Palumbo et al. showed that lenalidomide 
maintenance similarly prolonged PFS (41.9 months) compared to no maintenance therapy 
(21.9 months); however, 3-year OS did not significantly increase (Palumbo et al., 2014).  
McCarthy et al. also looked at the effects of lenalidomide administered post-
ASCT in 460 patients. Post-ASCT, patients were randomly assigned lenalidomide or a 
placebo. After a 34-month follow-up, the PFS was 46 months for the lenalidomide group 
versus 27 months observed in the placebo group (McCarthy et al., 2012). Consistent with 
similar RCTs, more adverse hematological and non-hematological events occurred in 
patients receiving lenalidomide (McCarthy et al., 2012). Second primary cancers 
occurred in 8% of patients in the lenalidomide arm versus 3% observed in the placebo 
group (McCarthy et al., 2012).  
Attal et al. published a similar RCT looking at the effect lenalidomide 
maintenance treatment has on PFS, post ASCT. They reported that lenalidomide group 
had a median PFS of 41 months compared to 23 months observed in the placebo group 
(Attal et al., 2012). Grade 3 or 4 AEs were similar for the 2 groups (Attal et al., 2012). 
Median event-free survival (events including second primary cancers) was 40 months in 
the lenalidomide group compared to 23 months observed in the placebo group (Attal et 
al., 2012). Despite promising increased PFS results, 4-year OS was similar (Attal et al., 
2012).  
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A meta-analysis by Wang et al., looking at 18 RCTs and 7,730 patients confirms 
these findings that IMiD-based maintenance therapies improves PFS (and therefore, 
better early disease control) but not OS in multiple myeloma (Wang et al., 2015).  
 
Novel agent maintenance regimens in older patients 
Unsurprisingly, as patients age, prognosis and overall outcomes are often poorer. 
Ozaki et al. looked at whether novel agents improved the prognosis of older MM patients 
who have undergone ASCT. Compared with just novel agents alone and conventional 
chemotherapy with ASCT, novel agents with ASCT showed the highest increase in PFS 
at 35.2 months and 5-year OS rate was 87%, nearly 20% higher than other therapies plus 
ASCT and 47% higher than novel agent regimens without ASCT (Ozaki et al., 2014). 
These results suggest that ASCT treatment plus novel agent maintenance could best 
prolong PFS and OS, in both younger newly diagnosed patients and older and more 
vulnerable patients.  
 
IMiD-based regimens in non-transplant setting 
Although many studies have concluded that novel agent therapy plus ASCT 
provide patients with the best outcomes, some patients are ineligible for transplant and 
only can just continue their maintenance therapies. Melphalan-prednisone-thalidomide 
(MPT) or Melphalan-prednisone-lenalidomide (MPR) therapy is standard for such 
patients however, Benboubker et al. hypothesized that use of lenalidomide-
dexamethasone (Rd) combination treatment could just be as effective (Benboubker et al., 
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2014). In their 1,623 patient study, they randomly assigned patients to Rd-treatments 
(continuous or in 28-day cycles) or to MPT for 72 weeks and looked at PFS. For 
continuous Rd treatment was 25.5 months, 20.7 months with Rd-treatment cycles, and 
21.2 months with MPT (Benboubker et al., 2014). With continuous Rd treatments, the 4-
year OS improved by 8% compared with MPT (Benboubker et al., 2014). Rd 
combination treatments were also associated with fewer Grade 3 or 4 AEs, hematologic, 
and neurologic toxic events (Benboubker et al., 2014).  
Gay et al. retrospectively studied 411 patients to compare the efficacy and toxicity 
of Rd treatment versus thalidomide-dexamethasone (Td) as a first-line therapy for MM 
patients. Although Gay et al.’s study was not a RCT, the group concluded that higher 
percentage of patients treated with Rd (80.3%) had at least a partial response compared to 
those receiving Td treatment (Gay et al., 2009. Time to disease progression was also 
longer for patients receiving Rd (Gay et al., 2009). With less Grade 3 or 4 AEs reported, 
Rd combination therapy seemed to be better tolerated and more effective than therapies 
with thalidomide (Gay et al., 2009).  
Yang et al., in their meta-analysis of lenalidomide RCTs, showed that 
lenalidomide increases improves response rates and increases PFS. The group compared 
the effects of using lenalidomide as first line versus second line treatments, through a 
meta-analysis. From 7 trials, they concluded that lenalidomide-based regimens showed 
increased complete response (CR) and very good partial response (VGPR) when 
compared to the placebo control group (Yang et al., 2013). Lenalidomide also increased 
PFS, however the prevalence of adverse events, such as neutropenia, deep-vein 
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thrombosis (DVT), infections, and other hematological cancers, associated with drug 
treatment was high compared to placebo (Yang et al., 2013).   
Results from these studies are unsurprising, as lenalidomide was designed to be 
less toxic and more potent; however, a more controlled RCT would have provided better 
confirmation of these results. It also suggests again that IMiDs are able to work 
synergistically with other drugs, (in this case, dexamethasone, a steroid) to provide 
deeper responses. 
 
IMiD-based Regimens in Relapsed and/or Refractory (R/R) Multiple Myeloma 
Although the aim of multiple myeloma treatment to extend the duration of disease 
remission, often patients relapse. Patients are defined to have relapsed and/or refractory 
(R/R) multiple myeloma either if they show little response to treatment or if their disease 
progresses within 60 days of therapy (Raka et al., 2017). Patients that either have high-
risk cytogenetics or did not receive maintenance or consolidation therapies post-ASCT 
had a higher risk of relapse (Cornell et al., 2017). Although treatment options are more 
limited due to possible cancer resistance, salvage chemotherapy, an additional ASCT 
procedure, robust consolidation/maintenance therapies are still available to patients. 
IMiDs are crucial components of maintenance therapy and their benefits are highlights in 
many RCTs that tested their efficacy in patients with relapsed disease. 
There is substantial evidence in the literature that lenalidomide is one IMiD that 
makes a major impact on extending patient PFS and OS. Wang et al., 2008 published 
RCT assessing the efficacy of lenalidomide-dexamethasone (Rd) therapy versus placebo-
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dexamethasone in 708 patients with R/R multiple myeloma. This study is notable because 
a significant percentage of patients, nearly 39%, were previously treated with thalidomide 
(Wang et al., 2008). The group showed that the lenalidomide combination therapy led to 
longer PFS, objective response rate (ORR), and longer time to progression compared to 
control (Wang et al., 2008). Among the Rd-treatment arm, although ORR was higher in 
patients not previously exposed to thalidomide, prior exposure did not affect survival and 
toxicity profiles were similar for both groups of patients (Wang et al., 2008). The results 
of this study demonstrate that administering lenalidomide is still beneficial for 
previously-treated patients with R/R multiple myeloma, despite the risk of thalidomide 
resistance. 
Similarly, Weber et al. published a randomized clinical trial testing the efficacy of 
a lenalidomide-dexamethasone for patients with relapsed multiple myeloma and 
concluded that nearly 61%, out of 177 patients in the experimental arm, had complete, 
near-complete, or partial responses, compared to 19% in the placebo-arm showing some 
sort response, and PFS was extended by nearly 6 months (Weber et al., 2007). Despite 
the frequent occurrence of Grade 3 or 4 adverse events, the study concluded that the 
combination therapy was superior to control for patients with relapsed disease, suggesting 
that IMiDs synergistically interact with other drugs to cause a greater therapeutic effect.  
These studies only represent a snapshot of all the studies in the literature. Van 
Beurden-Tan et al. published a large meta-analysis of all treatment options of R/R MM 
and their efficacies using clinical data obtained from 17 RCTs. Using hazard ratios to 
control for statistical and administrative differences across different RCTs, the group 
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concluded that the combination of daratumumab, lenalidomide, and dexamethasone was 
best the treatment option. This combination reduced the risk of progression or death 
significantly, by nearly, 80% or more compared to other treatment options like 
dexamethasone, or combinations of lenalidomide and bortezomib with dexamethasone. 
Although the study was limited by the fact that most RCTs do not necessarily compare 
different treatments head-to-head and did not consider potential AEs these treatments 
have on quality of life, their conclusions indicate lenalidomide, in combination with other 
drugs, is a good, viable option for patients suffering from R/R multiple myeloma, and 
historically seems to perform better than other combinations, namely those that contain 
bortezomib  
 
Bortezomib-based regimens 
Although this section primarily focuses on RCTs or meta-analyses looking at 
IMiD-based regimens, it is imperative to look at the efficacy data on bortezomib, 
considering several meta-analyses suggesting bortezomib-based regimens are marginally 
superior to those containing IMiDs.  
Nooka et al., published a meta-analysis of Phase III RCTs looking at Bortezomib-
containing induction regimens and their efficacies and seeing the effect of such 
treatments in MM patients post-ASCT transplantation. Historically, high-dose 
chemotherapy (HDT)-ASCT has been able to improve OS; however, since the 
introduction of novel agents, there have been few studies correlating the impact of 
induction therapies for younger patients who eventually undergo ASCT. Looking at 
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2,169 patients and pooling data through hazard ratios, similar to other meta-analyses, the 
group concluded that induction regimens containing bortezomib improved post-transplant 
PFS and OS outcomes (Nooka et al., 2013), suggesting that the choice of induction 
therapy can affect outcomes for patients who choose to undergo ASCT.  
Although there have been a lot of meta-analyses comparing different treatment 
options and several RCTs combining IMiDs and PIs in combination, few studies have 
been run to directly compare bortezomib and IMiD regimens head-to-head. Gentile et al. 
analyzed the results of two phase III RCT to compare a bortezomib-melphalan-
prednisone regimen (VMP) versus a lenalidomide-dexamethasone IMiD-based treatment 
(Rd) administered over a 60-month follow-up period. Although the VMP treatment 
increased PFS in the first 12 months of the study, no difference was observed from 12-32 
months (Gentile et al., 2016). After 32 months, Rd-treated patients had increased PFS 
(Gentile et al., 2016). VMP however, showed increased OS throughout the period 
analyzed (Gentile et al., 2016). Although there seems to be less differences between the 
two treatment arms with increased time, initial increases in PFS could be associated with 
increased tumor reduction and therefore better disease control associated with VMP 
treatment. 
Like thalidomide’s newer analogs, lenalidomide and pomalidomide, bortezomib 
has been similarly revamped as carfilzomib. Carfilzomib is a next-generation proteasome 
inhibitor, approved by the FDA in 2012, that binds irreversibly to the 20s proteasome 
(Dimopoulos et al., 2017). In 2017, a phase ASPIRE study was published by Dimopoulos 
et al. that analyzed the clinical effects of adding carfilzomib to lenalidomide-
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dexamethasone (Rd) treatments. Bortezomib, historically the major proteasome inhibitor 
used in multiple myeloma treatment, binds proteasomes but less selectively. The ASPIRE 
trial showed that addition of carfilzomib to Rd treatments improved PFS compared to 
control (Rd alone). When the trial results were reanalyzed to organize outcomes based on 
ages of patients, for patients younger than 70 years old, carfilzomib extended PFS by 
around 11 months when compared to controls and ORR was 86% compared to 66.9% in 
control arms (Dimopoulos et al., 2017). For patients older than 70, the PFS improvement 
was only 6 months and objective (ORR) was 90.3% compared to 66.1% in control arms 
(Dimopoulos et al., 2017). These recent Phase III clinical trials suggest that using 
carfilzomib, an improved proteasome inhibitor, in addition with lenalidomide and 
dexamethasone, extends life expectancy of multiple myeloma patients. Although for 
older patients, there was a greater risk of adverse cardiovascular events, using carfilzomib 
seems to be a beneficial addition to multiple myeloma treatment.  
Although the development of more potent IMiDs has significantly advanced 
treatment for multiple myeloma, it must not be forgotten that it is merely one drug out of 
multiple drugs needed. Efforts now are directed at seeing if other drugs used in induction 
treatments can be improved and made more potent. 
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DISCUSSION 
 
The risks and benefits of IMiD treatment 
Although there is substantial evidence that IMiDs should be taken with caution 
and are not a cure-all, there is overall agreement that collectively, novel agents like 
IMiDs and proteasome inhibitors have made a tremendous impact, especially when used 
in induction and maintenance therapies, changing the way the disease is treated and 
managed today.  
However, the challenges of bringing IMiDs to the clinic are realized when the 
observations seen in vitro are not completely reflected in the clinical data, as in vitro and 
in vivo models are ultimately not the same. As discussed, randomized trials have shown 
with or without autologous stem cell transplantation (ASCT), maintenance with IMiDs 
has notable beneficial effects on extending progression free survival (PFS). The overall 
survival (OS) benefit from IMiD maintenance therapy is not as clear, given the 
differences in treatment administration between individual studies and the difficulty of 
long-term follow-up studies. Aside from the enormous costs of IMiD maintenance 
therapy, the fact that IMiDs are toxic compounds with severe side effects, especially 
thalidomide, warrants a discussion about the benefits and risks of using such a treatment 
regimen. IMiDs like lenalidomide increase patient risk for hematological adverse events, 
such as thromboembolic events and neutropenia, as well as second primary malignancy 
(Nathwani et al., 2016). Thalidomide, on the other hand, causes non-hematological 
toxicities that are more likely to cause treatment discontinuation, like peripheral 
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neuropathy, mood disturbances, and adverse gastrointestinal side effects (Nathwani et al., 
2016). 
 
Addressing inconsistencies in clinical data 
Given the sheer number of randomized clinical trials testing different therapies 
and different combinations of those therapies in multiple myeloma patients, both in 
transplant and non-transplant settings, it is a challenge to interpret data and determine 
what exactly is the best treatment out there. Most studies generally only compare 2 or 3 
treatment combinations and more rarely do studies include proper placebo control groups. 
Even when comparing different studies using the same treatment groups, there are always 
differences in patient populations, drug administration, and data analysis, and author bias 
in data interpretation, which could account for differing or contradictory conclusions. 
When these differences occur, it is difficult to say whether they are caused by 
experimental conditions or just the treatments themselves. It is possible certain 
combinations of drugs are less effective because of unfavorable drug interactions. 
Although from the current clinical data, it is inconclusive whether bortezomib or 
IMiD-based regimens give better results, there are also many other things to factor in 
when prescribing treatment, including patient history, personal tolerability of the drug, 
and occurrence of unexpected adverse events that affect quality of life. IMiDs, regardless, 
give patients treatment options that did not exist decades before. Their success clinically 
also provides opportunities for researchers in academia and industry to explore newer, 
more targeted analogs that further increase the duration of progression-free disease and 
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overall survival. 
 
Future Directions in Research 
 Despite all the positive clinical data and more recently, break-through 
publications demonstrating IMiDs’ mechanism of action, clearly more research needs to 
be done, beginning with understanding of how IMiDs are able to combat malignant cells. 
Only from a more detailed understanding of mechanisms can more targeted drugs be 
developed to treat patients. As described previously, novel discoveries have been made to 
determine IMiDs’ mechanism of action and this foundational research has opened up 
opportunities to discover further therapeutic targets and biomarkers through the IMiD-
cereblon/IKZF-mediated signaling pathway. Crystal-structure knowledge of IMiD 
binding to cereblon provides additional opportunities to develop new analogs that 
selectively turn on CRBN-mediated degradation (Fischer et al., 2013). The research in 
vitro, so far, has shown that interrupting this aberrant signaling pathway can effectively 
kill malignant plasma cells; however, it is clear there is much that is not yet understood.  
 IMiDs bind to cereblon and cause downstream inhibition of IKZF1 and IKZF3 
transcription factors through proteasomal degradation. In theory, the addition of 
proteasome inhibitors like bortezomib should be inhibiting some part of this degradation 
process, impairing the ability of IMiDs to trigger its downstream effects. However 
clinically, this is not the case, as combination therapies combining these two drugs 
together have been used with great effect. Likely their synergistic effect points to the 
existence of separate, independent pathways that have yet to be discovered. This 
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synergistic effect may also be caused by order of administration, as it has been shown 
that when dosed together, lenalidomide-induced degradation occurs before proteasomal 
activity is inhibited (Fink et al., 2015). 
 Given the numerous effects IMiDs have on multiple myeloma cells and related B-
cell cancers and their synergistic effects with other drugs, it is likely that the full IMiD 
MOA is far more complicated than previously thought. The cereblon-mediated pathway 
itself causes widespread effects downstream; in combination with other speculated 
pathways being triggered or modulated, it is possible there are still undiscovered 
downstream targets. This might explain why studies have shown that although 80% of 
patients responsive to IMiD-based regimens express high levels of CRBN, and that lack 
of CRBN indicates high probability of IMiD-resistance (Schuster et al., 2014), there is no 
difference in expression of downstream factors IKZF1/3 between those that respond to 
treatment and those that do not (Huang et al., 2013). There is some evidence that 
indicates that IKZF1 expression can be predictive of decreased IMiD responsiveness and 
shorter overall survival (Zhu et al., 2014), however this remains a matter that has to be 
further addressed. 
There is also a question of genetic profiling of MM patients and what mutations 
contribute to drug-resistant MM. It is known that there are certain subpopulations of MM 
patients with high-risk (HR) cytogenetics that generally display poorer outcomes despite 
aggressive treatment and ASCT (Chakraborty et al., 2017). Today, there are methods to 
not only profile patients by fluorescence in situ hybridization (FISH) but also define end-
point markers that are clinically predictive of patient outcomes (Chakraborty et al., 2017). 
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However, most MM exomes sequenced thus far have been obtained from newly 
diagnosed patients, which do not show mutations due to prolonged treatment (Kortum et 
al., 2016). Recently, sequencing studies screening patients with refractory MM, those 
insensitive to novel agents, have been performed, showing increased prevalence of 
mutations in Ras pathway genes, TP53, and CRBN (an IMiD binding target) (Kortum et 
al., 2016), which are all potentially targetable genes. The genetic makeup of MM, 
unsurprisingly, changes with time and exposure to treatment, a common feature of 
cancer. The identification of CRBN mutations in nearly 22% of patients analyzed in this 
study suggests high probability of IMiD-induced clonal selection, which explains why 
some patients eventually become drug-resistant (Kortum et al., 2016). Overall, the 
prevalence of gene mutations suggests high levels of tumor heterogeneity that might also 
explain why different clinical studies show inconsistent results, as it is dependent on 
patient population. Likely more genetic analyses will be done in the future, to determine 
which subpopulations of patients benefit the most from certain treatment regimens.  
 
Future Directions in Clinical Studies 
Clinically, there are many ongoing RCTs testing new combinations and new 
analogs to treat MM. Novel immunotherapy treatments are in clinical development, from 
monoclonal antibodies, to chimeric antigen receptor (CAR) T-cell therapy, checkpoint 
blockade drugs and cancer vaccines (Nathwani et al., 2016).  
Just as important as the results of new RCTs is continued standardization and 
optimization of care for patients. This could involve anything from clinicians properly 
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defining certain endpoints or clinical observations that warrant certain treatments to 
further research to find reliable and predictive biomarkers during course of disease 
treatment. The minimal residual disease (MRD) assessment is one such factor slowly 
gaining importance in MM treatment evaluation, as several studies have demonstrated it 
to be a reliable feature of adverse outcomes, especially for high-risk patients with 
aggressive disease (Raza et al., 2017; Nathwani et al., 2016).  
Another optimization of care feature that should be better explored is the 
identification of patient risk factors that significantly affect treatment efficacy, like 
personal fitness. Clinicians should also consider not only patient risk factors but also the 
impact such toxic regimens have on quality of life. Although some RCTs are beginning 
to factor in these impacts into their studies, it is not a commonly observed practice. 
Treatment, after all, should be aimed at not only slowing progression of disease but 
improving the quality of life during treatment. 
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CONCLUSION 
 
Immunomodulatory drugs (IMiDs) are a class of compounds derived from 
thalidomide that have made a tremendous impact on the multiple myeloma treatment and 
cancer research. From the abundance of research detailing their immunomodulatory and 
anti-inflammatory effects. IMiDs seem to affect malignant cells through three major 
strategies of treatment: 1) increasing the adaptive immune response by increasing T and 
NK cell activities, 2) inhibiting the release of inflammatory molecules that promote 
cellular adhesion and angiogenesis, and 3) directly inhibiting cell growth by inhibiting 
proliferation pathways and promoting cellular apoptosis. The precise mechanisms for 
most of these capabilities still remain a mystery; however, discovery of one major IMiD-
binding target, cereblon, has opened up new areas of research that likely will lead to 
further elucidation of the full IMiD mechanism of action, including yet to be discovered 
downstream targets and implicated cellular pathways. 
Given the abundance of research showing IMiDs effect in vitro and clinical data 
showing the impressive impact IMiDs have had on extending progression-free survival, it 
is clear that IMiDs are useful, potent drugs able to slow down cancer progression and 
extend duration of patient survival, especially when used with other drugs like 
proteasome inhibitors and corticosteroids. Although in the literature, it is difficult to 
ascertain which combination therapy seems the most effective, likely more studies will be 
done in the future to directly compare different treatments. Improved understanding of 
the genetic abnormalities behind multiple myeloma can also help clinicians determine 
which therapies their patients will benefit most from. In addition, improved methods of 
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tracking disease progression and treatment response through biomarkers will help to 
further enhance care. Although biochemical and clinical research efforts are important, it 
is also important to factor in how such treatments affect disease management and quality 
of life of patients.  
From a disease that was essentially a death sentence just decades ago, multiple 
myeloma has now evolved into a disease that is now treatable, at least in the short term, 
and manageable, without additional toxic chemotherapeutics. Aside from providing 
patients with increasingly potent therapies, IMiDs have also enhanced researchers’ 
understanding of related B-cell cancers and general disease biology. Such discoveries 
will not only allow for further opportunities to chemically optimize and improve current 
novel therapies, but also lead to new, potentially druggable, targets. 
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APPENDIX 
		Study Study Type Novel Agent Therapies Compared ASCT status Number of Patients Conclusions Adverse Events
Wang et al., 
2016
Meta-
analysis (17 
RCTs)
Thalidomide, 
Lenalidomide, 
Bortezomib
with and 
without 6742
Novel agents 
increased PFS 
regardles of 
ASCT status. OS 
increased in 
bortezomib and 
thalidomide 
regimens 
without ASCT
hematologic 
events, GI 
events, 
peripheral 
neuropathy, 
thrombosis 
associated with 
novel agent 
regimens
Zou et al., 
2013
Meta-
analysis (10 
RCTs)
Bortezomib, 
Lenalidomide without 4534
Only 
Bortezomib 
front-line 
therapes 
increased OS. 
Lenalidomide 
and Bortezomib 
addition 
increased PFS
herpes zoster, 
peripheral 
neuropathy, GI 
effects 
associated with 
Bortezomib. GI 
events, 
thromboemboli
c events, 
second primary 
cancers 
associated with 
Sonneveld et 
al., 2013
Meta-
analysis (4 
RCTs)
Bortezomib-based 
(bortezomib-
dexamethasone, 
bortezomib-doxorubicin-
dexamethasone, 
bortezomid-
thalidomide-
dexamethasone), Non-
bortezomib-based 
(vincristine-doxorubicin-
dexamethasone, 
thalidomide-
dexamethasone)
with 1572
Bortezomib-
based 
increased PFS 
and OS with 11-
weeks of 
induction 
treatment
Bortezomib 
based regimens 
had increased 
rate of 
peripheral 
neuropathy
Wang et al., 
2014
Meta-
analysis (14 
RCTs)
Bortezomib-
thalidomide, 
bortezomib-
lenalidomide, 
bortezomib doxorubicin
both 5379
Bortezomib-
thalidomide 
increased only 
complete 
remission (CR) 
and overall 
response rate 
(ORR). 
Bortezomib-
doxorubicin 
only increased 
CR. Bortezomib-
lenalidomide 
increased PFS 
and OS only.
Bortezomib-
thalidomide 
had increased 
rate of 
peripheral 
neuropathy, 
thrombotic 
events, 
infection, no 
significantly 
increased 
events for 
other two 
regimens
Wang et al., 
2016
Meta-
analysis (5 
RCTs)
Bortezomib-
lenalidomide/thalidomi
de, Bortezomib or 
lenalidomide/thalidomi
de
without 1200
Bortezomib-
lenalidomide/t
halidomide 
induction 
regimens 
improved CR
no increase in 
peripheral 
neuropathy, 
thrombotic 
events, 
infection 
associated with 
combination 
therapy
Table 2: A summary of meta-analyses analyzed that compare IMiD-based regimens 
with Bortezomib-based regimens. 
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Study Study Type
Novel Agent 
Therapies Compared ASCT status
Number of 
Patients Conclusions Adverse Events
Stewart et al., 
2012 phase 3 RCT
melphalan-
prednisone-
thalidomide, 
melphalan-
prednisone, 
lenalidomide
without 306
Melphalan-
prednisone-
thalidomide 
increased PFS and 
OS compared to 
treatment with 
lenalidomide
Increased grade 
3 non-
hematological 
toxicity and 
secondary 
malignancies for 
thalidomide 
combination 
threatments. 
Lenalidomide 
regimen better 
tolerated
Cornell et al., 
2017 RCT
Post transplant 
therapy 
(lenalidomide/bortez
omib-
dexamethasone, 
bortezomib-
lenalidomide-
dexamethasone, 
cyclophosphamide-
bortezomib-
dexamethasone) vs. 
no therapy post 
with 693
Post-transplant 
therapy, 
regardless of 
regimen choice, 
increased 3 year 
PFS; no difference 
in OS observed
no significant 
levels of AE's 
reported
Palumbo et al., 
2014 phase 3 RCT
melphalan post ASCT 
vs. melphalan 
consolidation 
therapy; 
lenalidomide 
maintenance vs. no 
maintenance
with and 
without
273 to 
melphalan 
study; 251 
to 
lenalidomid
e study
Melphalan post 
ASCT increased 
PFS and 4-year 
OS. Lenalidomide 
maintenance 
increased PFS but 
not 3-year OS
increased 
neutropenia 
with, GI adverse 
events for 
melphalan post 
ASCT treatment; 
increased 
neutropenia and 
dermatologic 
effects 
associated with 
lenalidomide 
maintenance
McCarthy et 
al., 2012 RCT
lenalidomide 
maintenance vs. 
placebo
with 460
Lenalidomide 
maintenance 
increased median 
time to 
progression.
increased 
hematologic and 
non-hematologic 
AE's, second 
primary cancers, 
associated with 
lenalidomide 
maintenance 
therapy
Attal et al., 
2012 phase 3 RCT
lenalidomide 
maintenance vs. 
placebo
with 614
Lenalidomide 
maintenance 
increased PFS, 
median event free 
survival and 4-
year OS
increased 
incidence of 
second primary 
cancers 
associated with 
lenalidomide 
treatment
Table 3: A summary of studies tested safety and efficacy of IMiD-based 
regimens with or without autologous stem cell transplantation (ASCT). 
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Table 3 (cont.) 
Study Study Type
Novel Agent 
Therapies Compared ASCT status
Number of 
Patients Conclusions Adverse Events
Wang et al., 
2016
meta-
analysis (18 
RCTs)
thalidomide, 
lenalidomide
with and 
without 7730
IMiD-based 
maintenance 
increased PFS but 
not OS, regardless 
of transplantion 
setting
increased peripheral 
neuropathy associated 
with thalidomide, 
increased risk of 
myelosuppression, 
thromboembolism and 
second primary cancer 
with lenalidomide,
Ozaki et al., 
2014
retrospectiv
e study
conventional 
chemotherapy with 
or without ASCT vs. 
novel agent 
regimens with or 
without ASCT
with and 
without 318
Novel agents with 
ASCT increased 
PFS and OS, even 
post relapse, 
compared to 
conventional 
chemotherapy
not considered
Benboubker et 
al., 2014 RCT
lenalidomide-
dexamethasone 
(different dose 
schedules); 
melphalan-
prednisone-
thalidomide
without 1623
Continuous 
lenalidomide-
dexamethasone 
increased PFS, OS 
compared to 
cyclic 
lenalidomide 
treatment and 
melphalan 
treatment
increased 
hematological, 
neurologic events, 
infections, second 
primary cancers were 
associated with 
melphalan 
combination 
treatment
Gay et al., 
2009
retrospectiv
e study
lenalidomide-
dexamethasone vs. 
thalidomide-
dexamethasone
without 411
Lenalidomide-
dexamethasone 
associated with 
increased PFS and 
OS
neutropenia mainly 
associated with 
lenalidomide 
treatment, 
thromboembolism and 
peripheral neuropathy 
asscoaited with 
thalidomide treatment
Yang et al., 
2013
meta-
analysis (7 
RCTs)
lenalidomide 
regimens vs. placebo
with and 
without
RCTs 
contained 
sample sizes 
from N=192-
614
Lenalidomide as 
first and second 
line therapy 
increased PFS, 
and rates of 
complete 
response (CR) and 
very-good partial 
response (VGPR)
neutropenia, deep 
vein thrombosis, 
infection, hematologic 
cancer  associated 
with lenalidomide 
treatment 
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Study Study Type
Novel Agent 
Therapies 
Compared ASCT status
Number of 
Patients Conclusions Adverse Events
Wang et al., 
2008 RCT
lenalidomide-
dexamethason
e vs. placebo-
dexamethason
e
unknown 704
lenalidomide-
dexamethasone 
increased PFS, 
time to 
progression 
(TTP), overall 
response rate 
(ORR)
increased venous 
thromboembolism
, 
myelosuppression, 
infections 
associated with 
lenalidomide-
dexamethasone
Weber et al., 
2007 RCT
lenalidomide-
dexamethason
e vs. placebo-
dexamethason
e
unknown 353
lenalidomide-
dexamethasone 
increased 
median OS, time 
to progression 
(TTP)
increased 
neutropenia, 
venous 
thromboembolism 
associated with 
lenalidomide 
group
Van Beurden-
Tan et al., 
2017
meta-
analysis (17 
RCTs)
thalidomide, 
lenalidomide, 
pomalidomide, 
bortezomid, 
carfilzomib, 
novel antibody 
treatments
unknown
RCTs 
contained 
sample size 
ranging 
from N=64-
465
lenalidomide-
daratumumab-
dexamethasone 
associated with 
highest increase 
in PFS, lowest 
risk of 
progression or 
death
not considered
Table 4: A summary of studies that tested safety and efficacy of IMiD-based 
regimens for relapsed and/or refractory multiple myeloma. 
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Study Study Type
Novel Agent 
Therapies 
Compared ASCT status
Number of 
Patients Conclusions Adverse Events
Nooka et al., 
2013
meta-
analysis         
(4 RCTs)
bortezomib 
induction vs. non-
bortezomib 
induction 
with 2169
Bortezomib 
induction regimens 
were associated 
with increased PFS 
and OS, post-ASCT
increased 
peripheral 
neuropathy and 
varicella-zoster 
virus reactivation 
associated with 
bortezomib 
regimen
Gentile et al., 
2016
comparison 
of 2 RCTs
bortezomib-
melphalan-
prenisone vs. 
lenalidomide-
dexamethasone 
without 479
Bortezomib 
induction regimen 
was associated 
with reduced 
disease 
progression prior 
to 32 months, and 
higher OS. After, 
lenalidomide 
patients had lower 
incidence of 
disease 
progression
increased 
hematologic AE's 
and non-
hematologic AE's 
associated with 
bortezomib 
regimen
Dimopoulos et 
al., 2017 phase 3 RCT
carfilzomib-
lenlidomide-
dexamethasone 
vs.l lenalidomide-
dexamethasone
unknown 396
Carfilzomib 
treatment 
increased median 
PFS and overall 
response rate 
(ORR)
increased 
cardiovascular 
adverse events 
associated with 
carfilzomib 
treatment
Table 5: A summary of studies that tested the safety and efficacy of Bortezomib-
based regimens. 
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